All articles tagged with #glp 1 drugs
Walmart will cover over 250 prescriptions, including insulin and diabetes-focused GLP-1s, at no cost to employees in 2027. The retailer is also adding 12 weeks of NICU leave and expanding specialist access for rare diseases, while keeping premium increases minimal.
New data from Eli Lilly and Novo Nordisk suggests GLP-1 drugs like tirzepatide and semaglutide may slow biological aging by two to four years. While animal studies show lifespan extensions, experts caution that benefits in healthy, non-obese individuals remain unproven.
Eli Lilly and Novo Nordisk presented data at the Aging Research & Drug Discovery conference showing that their GLP-1 weight-loss drugs, semaglutide and tirzepatide, may reverse biological aging by two to three years in patients with obesity or type 2 diabetes. Using molecular 'aging clocks,' researchers found that these medications slow the molecular time of aging in various organs, with some clocks showing a reduction of up to four years. While the findings are promising, they are based on unreviewed data and do not yet prove that the drugs will extend lifespan or improve health outcomes in healthy populations. Further research is needed to determine the long-term effects of these drugs on aging.
A new report by Deep Science Ventures (DSV) claims that modern vegetables contain 20% to 50% less essential nutrients than they did in the 1960s. The decline is attributed to decades of breeding for yield rather than nutritional quality, combined with soil degradation and fertilizer regimes that boost biomass without mineral uptake. While independent studies confirm drops in specific minerals like iron and zinc, experts caution that the 'half as nutritious' headline oversimplifies complex data. DSV warns that if GLP-1 weight-loss drugs reduce calorie intake while nutrient density continues to fall, millions of UK adults could face micronutrient deficiencies by 2050. Solutions proposed include better soil management, biofortified crop breeding, and new market incentives for nutrient-dense produce.
The World Health Organization released its first global guidelines for managing childhood obesity, explicitly advising against the use of GLP-1 weight-loss medications, bariatric surgery, or weight-management devices for children under 10. For adolescents aged 10 to 19, medical interventions are permitted only after supervised lifestyle programs fail. The guidelines emphasize healthy eating, physical activity, and digital tools as primary strategies, citing a quadrupling of obesity rates in this age group since 1990.
A new study of nearly 2,000 people finds that GLP-1 weight-loss drug users are significantly more likely to experience nail detachment and hair loss than non-users. While the association is strong, experts caution that rapid weight loss and nutrient deficiencies, rather than the drugs themselves, may be the primary cause.
US health spending is projected to exceed $6 trillion in 2026, driven primarily by high provider prices rather than increased care volume. Employers face an estimated 8.2% to 11.1% cost increase for 2027, the largest jump in decades, fueled by GLP-1 drug usage and hospital consolidation. While insurers and providers cite volume and inflation, researchers argue that opaque pricing structures and lack of transparency allow hospitals and drug companies to charge multiples of Medicare rates, forcing workers to absorb higher premiums and deductibles.
New research suggests that fat cells retain an epigenetic 'memory' of obesity, keeping hunger hormones elevated even after weight loss. This biological mechanism may explain why patients regain weight quickly after stopping GLP-1 medications, highlighting the need for long-term metabolic management rather than short-term fixes.
Dr. Tommy Wood, a University of Washington neuroscientist, warns that rapid weight loss from GLP-1 medications like Ozempic and Wegovy can deprive the brain of essential energy. He explains that extreme caloric deficits may force the brain to consume its own white matter, similar to what happens during intense marathon running. While these drugs can improve cognitive health by lowering blood pressure and blood sugar in obese patients, severe under-eating risks long-term cognitive impairment. Wood advises pairing these medications with resistance training and ensuring adequate intake of neuro-nutrients like omega-3s, iron, and B vitamins to protect brain function.
Dr. Tommy Wood, a University of Washington neuroscientist, warns that rapid weight loss from GLP-1 drugs like Ozempic and Wegovy can deprive the brain of essential energy and nutrients. He explains that extreme caloric restriction may force the brain to consume its own tissue, while chronic under-eating reduces critical nutrients like iron, protein, and omega-3 fats. Wood advises pairing these medications with resistance training and ensuring adequate intake of neuro-nutrients to protect cognitive function.
Novo Nordisk presented real-world data indicating that patients switching from injectable obesity drugs to the new oral Wegovy pill continued losing weight. The analysis suggests the pill may offer convenience without sacrificing efficacy, potentially shifting patient preference away from weekly injections.
GLP-1 weight-loss drugs produce highly variable results, with some users losing over 20% of body weight while others see minimal change. Factors include genetics, emotional eating patterns, and diabetes status. A new Cleveland Clinic study indicates that many patients maintain weight loss after stopping medication through alternative treatments.
The American Association for Cancer Research's 2026 report notes that obesity is a major cancer risk factor, prompting interest in whether GLP-1 drugs like Ozempic and Mounjaro can reduce cancer incidence. While retrospective studies suggest lower cancer risk and higher survival rates for GLP-1 users, evidence remains mixed, with some studies showing increased risks for specific cancers like thyroid cancer. Dr. Sai Yendamuri of Roswell Park Comprehensive Cancer Center suggests these drugs may alter the body's immune response to fight cancer cells, potentially lowering recurrence rates in lung cancer and melanoma. However, randomized clinical trials are lacking, and it remains unclear if benefits stem from weight loss or direct immune effects. Future trials will determine if GLP-1s can serve as a preventive mechanism for cancer.
While GLP-1 medications like semaglutide and tirzepatide help many patients lose significant weight, 10–15% of users experience minimal or no results. Researchers are investigating why this occurs, with early evidence pointing to biological sex, oestrogen levels, and genetic factors as key drivers of individual response. The Endocrine Society has designated understanding this heterogeneity as a priority to enable personalized treatments.
Hundreds of lawsuits allege that popular weight-loss drugs like Ozempic and Mounjaro cause NAION, a rare condition leading to permanent vision loss. While manufacturers deny causation, some countries have updated drug labels to include this risk, and the FDA is reviewing the evidence.